Iron chelation therapy and lung transplantation: Effects of deferoxamine on lung preservation in canine single lung transplantation

John Conte, N. M. Katz, M. L. Foegh, R. B. Wallace, P. W. Ramwell

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Reperfusion injury is a limiting factor in lung transplantation. Deferoxamine is an iron chelator that inhibits the formation of oxygen-derived free radicals. We investigated the effects of deferoxamine on posttransplantation lung function in a canine model of single lung transplantation. Tweleve dogs underwent left lung transplantation after 20- to 24-hour hypothermic storage in a modified Euro-Collins solution. In six experiments donor and recipient received a 10 mg/kg dose of deferoxamine before harvest and transplantation, and 10 mg/kg was added to the preservation solution. Arterial oxygen tension, alveolar-arterial oxygen difference, pulmonary vascular resistance, and dynamic lung compliance were measured. Data were recorded for 6 hours after ligation of the native pulmonary artery. At the end of the study the mean arterial oxygen tension was 175.1 mm Hg for the deferoxamine treated group versus 71.1 mm Hg for the control group (p < 0.001), and the alveolararterial oxygen difference was less in the deferoxamine-treated group: 502.3 versus 606.0 mm Hg (p < 0.001). The mean pulmonary vascular resistance was lower throughout the study, and after 6 hours it was 455.1 dynes/sec/cm-5 in the deferoxamine-treated group versus 663.7 dynes/sec/cm-5 in the control group (p < 0.035). Compliance was similar in both groups. We conclude that deferoxamine improves lung preservation and early posttransplantation function in canine single lung transplantation.

Original languageEnglish (US)
Pages (from-to)1024-1029
Number of pages6
JournalJournal of Thoracic and Cardiovascular Surgery
Volume101
Issue number6
StatePublished - Jan 1 1991

Fingerprint

Chelation Therapy
Deferoxamine
Lung Transplantation
Canidae
Iron
Lung
Oxygen
Vascular Resistance
Arterial Pressure
Lung Compliance
Control Groups
Chelating Agents
Reperfusion Injury
Pulmonary Artery
Compliance
Free Radicals
Ligation
Transplantation
Dogs

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{7e70db59c7eb461fab0a8bfaf5992d5e,
title = "Iron chelation therapy and lung transplantation: Effects of deferoxamine on lung preservation in canine single lung transplantation",
abstract = "Reperfusion injury is a limiting factor in lung transplantation. Deferoxamine is an iron chelator that inhibits the formation of oxygen-derived free radicals. We investigated the effects of deferoxamine on posttransplantation lung function in a canine model of single lung transplantation. Tweleve dogs underwent left lung transplantation after 20- to 24-hour hypothermic storage in a modified Euro-Collins solution. In six experiments donor and recipient received a 10 mg/kg dose of deferoxamine before harvest and transplantation, and 10 mg/kg was added to the preservation solution. Arterial oxygen tension, alveolar-arterial oxygen difference, pulmonary vascular resistance, and dynamic lung compliance were measured. Data were recorded for 6 hours after ligation of the native pulmonary artery. At the end of the study the mean arterial oxygen tension was 175.1 mm Hg for the deferoxamine treated group versus 71.1 mm Hg for the control group (p < 0.001), and the alveolararterial oxygen difference was less in the deferoxamine-treated group: 502.3 versus 606.0 mm Hg (p < 0.001). The mean pulmonary vascular resistance was lower throughout the study, and after 6 hours it was 455.1 dynes/sec/cm-5 in the deferoxamine-treated group versus 663.7 dynes/sec/cm-5 in the control group (p < 0.035). Compliance was similar in both groups. We conclude that deferoxamine improves lung preservation and early posttransplantation function in canine single lung transplantation.",
author = "John Conte and Katz, {N. M.} and Foegh, {M. L.} and Wallace, {R. B.} and Ramwell, {P. W.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "101",
pages = "1024--1029",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "6",

}

Iron chelation therapy and lung transplantation : Effects of deferoxamine on lung preservation in canine single lung transplantation. / Conte, John; Katz, N. M.; Foegh, M. L.; Wallace, R. B.; Ramwell, P. W.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 101, No. 6, 01.01.1991, p. 1024-1029.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Iron chelation therapy and lung transplantation

T2 - Effects of deferoxamine on lung preservation in canine single lung transplantation

AU - Conte, John

AU - Katz, N. M.

AU - Foegh, M. L.

AU - Wallace, R. B.

AU - Ramwell, P. W.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Reperfusion injury is a limiting factor in lung transplantation. Deferoxamine is an iron chelator that inhibits the formation of oxygen-derived free radicals. We investigated the effects of deferoxamine on posttransplantation lung function in a canine model of single lung transplantation. Tweleve dogs underwent left lung transplantation after 20- to 24-hour hypothermic storage in a modified Euro-Collins solution. In six experiments donor and recipient received a 10 mg/kg dose of deferoxamine before harvest and transplantation, and 10 mg/kg was added to the preservation solution. Arterial oxygen tension, alveolar-arterial oxygen difference, pulmonary vascular resistance, and dynamic lung compliance were measured. Data were recorded for 6 hours after ligation of the native pulmonary artery. At the end of the study the mean arterial oxygen tension was 175.1 mm Hg for the deferoxamine treated group versus 71.1 mm Hg for the control group (p < 0.001), and the alveolararterial oxygen difference was less in the deferoxamine-treated group: 502.3 versus 606.0 mm Hg (p < 0.001). The mean pulmonary vascular resistance was lower throughout the study, and after 6 hours it was 455.1 dynes/sec/cm-5 in the deferoxamine-treated group versus 663.7 dynes/sec/cm-5 in the control group (p < 0.035). Compliance was similar in both groups. We conclude that deferoxamine improves lung preservation and early posttransplantation function in canine single lung transplantation.

AB - Reperfusion injury is a limiting factor in lung transplantation. Deferoxamine is an iron chelator that inhibits the formation of oxygen-derived free radicals. We investigated the effects of deferoxamine on posttransplantation lung function in a canine model of single lung transplantation. Tweleve dogs underwent left lung transplantation after 20- to 24-hour hypothermic storage in a modified Euro-Collins solution. In six experiments donor and recipient received a 10 mg/kg dose of deferoxamine before harvest and transplantation, and 10 mg/kg was added to the preservation solution. Arterial oxygen tension, alveolar-arterial oxygen difference, pulmonary vascular resistance, and dynamic lung compliance were measured. Data were recorded for 6 hours after ligation of the native pulmonary artery. At the end of the study the mean arterial oxygen tension was 175.1 mm Hg for the deferoxamine treated group versus 71.1 mm Hg for the control group (p < 0.001), and the alveolararterial oxygen difference was less in the deferoxamine-treated group: 502.3 versus 606.0 mm Hg (p < 0.001). The mean pulmonary vascular resistance was lower throughout the study, and after 6 hours it was 455.1 dynes/sec/cm-5 in the deferoxamine-treated group versus 663.7 dynes/sec/cm-5 in the control group (p < 0.035). Compliance was similar in both groups. We conclude that deferoxamine improves lung preservation and early posttransplantation function in canine single lung transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0025947409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025947409&partnerID=8YFLogxK

M3 - Article

C2 - 2038195

AN - SCOPUS:0025947409

VL - 101

SP - 1024

EP - 1029

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 6

ER -